louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00466453: Adapting Web-based Instruction to Baseline Knowledge of Physicians-in-training
Official title: Adapting Web-based Instruction to Learner Baseline Knowledge: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Medical Education
Medical Training
Internship and Residency
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2007-04-27
Enrollment: 144
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The purpose of this study is to compare an adaptive Web-based learning system to a non-adaptive system for teaching physicians-in-training about ambulatory medicine.

Detailed description: Not all Web-based instruction is equally effective at facilitating learning. Adaptation to characteristics of individual learners may enhance Web-based learning by emulating a face-to-face teacher's response to a learner's needs. Learner baseline knowledge level is one variable to which Web-based instruction may adapt. We will enhance Web-based instructional modules used in the Internal Medicine resident continuity clinics so that they adapt to learner baseline knowledge. We will then compare the adaptive Web-based format to the standard format. We hypothesize that the adaptive format will have higher learning efficiency, and that achievement will be similar for the two groups. We also hypothesize that residents will prefer the adaptive format and find it to be more motivating than the standard format.

Eligibility criteria: Inclusion Criteria:

* Internal medicine residents (Mayo-Rochester campus)

Primary outcomes:
measure: Knowledge
measure: Learning efficiency
Secondary outcomes:
measure: Format preference
measure: Time to complete module
measure: Motivation
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: David A. Cook, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cook DA, Beckman TJ, Thomas KG, Thompson WG. Adapting web-based instruction to residents' knowledge improves learning efficiency: a randomized controlled trial. J Gen Intern Med. 2008 Jul;23(7):985-90. doi: 10.1007/s11606-008-0541-0.
Clinical trial NCT01358253: Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Official title: Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acute Lymphoblastic Leukemia
Keywords: Rituximab
HyperCVAD
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2011-05-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to evaluate the safety and efficacy of Rituximab combined with chemotherapy in CD20+ adult acute lymphoblastic leukemia.

Detailed description: Acute lymphoblastic leukemia (ALL) is a group of biologically heterogeneous diseases with diverse prognosis. Novel strategies for adult ALL have approached a CR rate of over 80%, which is similar to pediatric ALL. But the long term survival of adult ALL is only 30%-40%, much lower than pediatric patients.

In our trial, all the patients will first receive Vincristine 1.4mg/m2, max 2mg IV days 1,8,15,22, Daunorubicin 45mg/m2 IV days 1-3,Cyclophosphamide 750mg/m2 IV day 1 and prednisone 40-60mg/m2,by mouth days 1-14 (VDCP)regimen as initial induction therapy. If patients achieve complete remission after induction, they will be enrolled in our study for further consolidation and maintenance. If the tumor cells in bone marrow remain 5% to 20% after induction, the patients will receive VDCLP(VDCP+L-asparaginase 6000IU/m2 IV days5,7,9,11,13) and be enrolled until complete remission.

Rituximab is the main experimental intervention in our study.The consolidation regimen is HyperCVAD/MA or R-HyperCVAD/MA for totally 8 courses. The maintenance regimen includes 6-Mercaptopurine+Methotrexate for 24 months, Vincristine+Prednisone for the first 12 months, L-asparaginase in month 3 and 9 with or without Rituximab in month 6 and 12.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of CD20-positive ALL
* Adequate liver function (bilirubin less than or equal to 1.5\*ULN, unless considered due to tumor), and renal function (creatinine less than or equal to 1.5\*ULN, unless considered due to tumor)
* Signed informed consent

Exclusion Criteria:

* Prior history of treatment with high-dose Ara-C, MTX or rituximab
* Pregnant or lactating women
* History of allergy to rituximab
* Unable to sign informed consent
* Active replication of HBV
* History of stem cell transplantation

Primary outcomes:
measure: CR duration
timeFrame: After two 21-day courses
measure: disease free survival
timeFrame: 2 year
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital
state: Shanghai
Study officials:
affiliation: Department of hematology Ruijin Hospital/Shanghai Institute of Hematology
name: Weili Zhao, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02805153: PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
Official title: The Multi-center, Open-label,Randomized Comparison Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Breast Cancer
Keywords: PEG-rhG-CSF
Lead sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2016-06-17
Enrollment: 215
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy


Eligibility criteria: Inclusion Criteria:

* Patients with age between 18 and 70 years
* diagnosis of breast cancer patients
* chemotherapy naive
* Karnofsky Performance Status ≥ 70
* Written informed consent are acquired

Exclusion Criteria:

* uncontrolled infection
* Have accepted radiotherapy within 4 weeks before anticipated the study
* pregnancy
* Other situations that investigators consider as contra-indication for this study

Primary outcomes:
measure: the occurrence rate of grade IV neutropenia during the first chemotherapy cycle
timeFrame: through first cycle of chemotherapy,an average of 1 month
Secondary outcomes:
measure: the non-occurrence rate of grade IV neutropenia (ANC < 0.5 x 10^9/L)during the next three consecutive cycles chemotherapy(except the first chemotherapy cycle)
timeFrame: through the next three consecutive cycles chemotherapy,an average of 3 months
measure: the duration of grade IV neutropenia (ANC < 0.5 x 10^9/L) during the next three consecutive cycles chemotherapy(except the first chemotherapy cycle)
timeFrame: through the next three consecutive cycles chemotherapy,an average of 3 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00488553: Molecular Epidemiology of Lymphoma Patients
Official title: Molecular Epidemiology of Lymphoma Patients
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Lymphoma
Keywords: Lymphoma
Epidemiology
Lifestyle Factors
Questionnaire
Survey
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2007-06-20
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants in this study will include 400 with newly diagnosed lymphoma and 400 matched controls.

Brief summary: Primary Objectives:

1. To enroll and obtain, through questionnaires, risk factor information on all study participants to develop detailed demographic, epidemiologic and behavioral profiles.
2. To assess the influence of relevant epidemiologic covariates such as age, gender, smoking and family history of cancer on the panel of susceptibility biomarkers.
3. To evaluate the role of genomic instability in development of lymphomas.

Detailed description: This study will include individuals diagnosed with lymphoma and individuals with no history of cancer. Half of the participants in this study will have lymphoma, and half will have no history of cancer. Information from both groups will be compared to help researchers try to learn which factors may lead to the development of lymphoma.

If you agree to take part in this study, you will be asked to complete a questionnaire at M. D. Anderson. In this questionnaire, you will be asked about your demographics (such as your age, sex, etc.), certain environmental exposures (such as pollution), your medical history, family history, diet, and your past and present smoking and alcohol use habits. This questionnaire should take about 50 minutes to complete.

You will also have about 2 ½ tablespoons of blood drawn for special tests. These tests will look for any biologic factors (such as changes in your DNA) that may be linked to lymphoma. You will not be informed of the results of any of the testing done with your blood samples.

Your participation will be over in this study once your blood has been drawn.

This is an investigational study. Up to 800 participants will take part in this study. All will be enrolled at M. D. Anderson.

Eligibility criteria: Inclusion Criteria:

1. Cases only: Newly diagnosed, previously untreated patients with lymphoma as the primary cancer.
2. Age 18 years and older.
3. Willing to donate 30ml of blood.
4. Willing to complete a self-administered questionnaire.
5. Controls only: No prior cancer.

Exclusion Criteria:

1. Cases only: Prior history of cancer other than lymphoma.
2. Unable to speak or read English

Primary outcomes:
measure: To identify biologic (such as genes) and lifestyle factors that may increase a person's risk of developing lymphoma.
timeFrame: 4 Years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Randa El-Zein, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05344053: Community-based Precise Management for Patients With Coronary Artery Disease
Official title: Development and Assessment of the Precise Management and Rehabilitation Model of Coronary Artery Disease Under the Hierarchical Medical System
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Coronary Artery Disease
Keywords: Coronary Artery Disease
Risk Factor Control
Community-based Management
Secondary Prevention
Lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Sponsor class: OTHER
First posted: 2022-04-25
Enrollment: 480
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The community-based precise management for patients with coronary artery disease study is a prospective, cluster-randomized, open-labeled trial. The purpose of this trial is to test whether a community-based precise management and rehabilitation model under the hierarchical medical system could help improve the cardiovascular risk factors control in patients with coronary artery disease. Additionally, the trial will also evaluate the impact of the model on major cardiovascular adverse events in patients with coronary artery disease.


Eligibility criteria: Inclusion Criteria:

* Patients with prior myocardial infarction
* or receiving percutaneous coronary intervention or coronary artery bypass graft;
* or coronary artery stenosis≥50% defined by coronary angiography or coronary CT angiography

Exclusion Criteria:

* Refuse to sign the written informed consent;
* Patients without the ability to take care of themselves;
* Mental disorders;
* Alcoholics or drug addicts;
* Cannot be followed up for any reasons;
* Life expectancy\<1 year due to non-cardiovascular reasons.

Primary outcomes:
measure: Status of risk factors control of coronary artery disease
timeFrame: 1 year
Secondary outcomes:
measure: All-cause death
timeFrame: 1 year
measure: Readmission
timeFrame: 1 year
measure: Myocardial infarction
timeFrame: 1 year
measure: Coronary revascularization
timeFrame: 1 year
measure: Stroke
timeFrame: 1 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Infirmary of Industrial and Commercial Bank of China
state: Beijing
Study officials:
References:
Clinical trial NCT02229253: Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Advanced Hormone Sensitive Prostate Cancer
Lead sponsor: Ferring Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2014-09-01
Enrollment: 112
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be selected from prostate cancer patients in a hospital setting, meeting the inclusion criteria.

Brief summary: Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.


Eligibility criteria: Inclusion Criteria:

* Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer

Exclusion Criteria:

* Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded
* Planned intermittent or short-term (\< 12 months) degarelix treatment
* Planned addition of, or switch to another form of androgen deprivation therapy during the study

Primary outcomes:
measure: Cardiovascular event rate in hormone naïve prostate cancer patients with cardiovascular comorbidity at baseline, treated with degarelix in daily practice
timeFrame: Up to 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Gouda
country: Netherlands
facility: Groene Hart Ziekenhuis (there may be other sites in this country)
Study officials:
affiliation: Ferring Pharmaceuticals
name: Clinical Development Support
role: STUDY_DIRECTOR
References:
Clinical trial NCT05412953: Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain
Official title: Tonation Breathing Technique, a Non-Pharmacogenic Method to Ease Aromatase Inhibitor-Induced Musculoskeletal Symptoms - A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2022-06-09
Enrollment: 15
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This clinical trial evaluates how well tonation breathing techniques (use of a breathing and tonation \[creating sounds\]) works to ease pain joint and/or muscle pain in patients with stage I-III breast cancer and currently take an aromatase inhibitor. Tonation breathing techniques may help relieve pain in patients with stage I-III breast cancer who are receiving aromatase inhibitor.

Detailed description: PRIMARY OBJECTIVE:

I. To study impact of active participation of patients in producing tones in combination with breathing technique, i.e., tonation breathing techniques (TBT) to reduce aromatase inhibitor induced musculoskeletal symptoms.

OUTLINE:

Patients participate in tonation breathing techniques twice daily (or more if pain occurs) for 2 weeks. Patients also complete questionnaire at baseline and at 2 weeks.

Eligibility criteria: Inclusion Criteria:

* Females with stage I-III breast cancer taking adjuvant aromatase inhibitor (AI) (either standard dose of anastrozole 1 mg daily or letrozole 2.5 mg daily or exemestane 25 mg daily) for greater than 30 days experiencing AI induced musculoskeletal pain scores of 5 or higher on a Likert scale will be enrolled
* Subjects should have completed any planned surgery for breast cancer, chemotherapy and radiation therapy at least 30 days prior to enrollment
* Patients should have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
* Patients should be at least 18 years old with no maximum age limit

Exclusion Criteria:

* Patients should not have significant underlying pulmonary disease

Primary outcomes:
measure: Change in aromatase inhibitor induced musculoskeletal pain symptoms
timeFrame: Baseline to 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic in Rochester
name: Prema P Peethambaram, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06098053: Efficacy of Muscle Energy Technique Alone and in Combination With Interferential Therapy for the Treatment of Non-specific Low Back Pain.
Official title: Efficacy of Muscle Energy Technique Alone and in Combination With Interferential Therapy for the Treatment of Non-specific Low Back Pain.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Back Pain
Lead sponsor: Neuro Counsel Hospital, Pakistan
Sponsor class: OTHER
First posted: 2023-10-24
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Single blind RCT in which Two groups were formed
Primary purpose: TREATMENT

Brief summary: Single blind randomized control trail in which two groups were formed. Group A was given Muscle energy technique and Group B was given muscle energy technique in combination with Interferential therapy.

Detailed description: After getting the REC approval from The Neurocounsel Clinics, study was initiated from 21 May, 2023 to 20 September 2023. Sample size was calculated by Epitool which came 30. Following participants were included a) both genders b) age 20-50 years and followings were excluded a) DM b) Parkinson disease c) disc disorder d) MSK disorder were excluded from this study. Simple random sampling technique was used to randomize participants into two equal groups. group A was given MET and group B was given MET plus IFT. 2 sessions/week for 4 \& half weeks. Evaluation was done at PNS \& EQ-5D-5L (QoL). Pre and post test analysis was done by use of SPSS version 21 and level of significance was kept p\<0.05.

Eligibility criteria: Inclusion Criteria:

* both genders
* age between 20-50 years old
* non specific type of back pain

Exclusion Criteria:

* Diabetes Mellitus
* Parkinson disease
* Any other Musculoskeletal disorder

Primary outcomes:
measure: Pain numeric scale
timeFrame: 4 and half weeks
measure: short form of 36
timeFrame: 4 and half weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: The Neurocouncil Clinic
state: Federal
Study officials:
References:
Clinical trial NCT02751853: Effects of Acutely Elevated Afterload on Left Ventricular Contractility and Relaxation
Official title: Effects of Acutely Elevated Afterload oN Left VentRicular Contractility and RElaxation in Heart Failure With Preserved and Reduced Ejection Fraction
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Heart Failure
Lead sponsor: University of Luebeck
Sponsor class: OTHER
First posted: 2016-04-26
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Aim of the study is to assess the effects of abruptly increased afterload on left ventricular contractility and relaxation in patients with heart failure with preserved ejection fraction (HFPEF), patients with heart failure with reduced ejection fraction (HFREF), and patients without HFPEF or HFREF.


Eligibility criteria: Inclusion Criteria:

* Clinical indication for left and right heart catheterization
* HFPEF (Group 1) OR HFREF (Group 2) OR absent echocardiographic evidence of HFREF OR HFPEF(Group 3)

AND

* Sinus rhythm during invasive measurements
* Age ≥18 years
* Negative pregnancy test in women with childbearing potential
* Written informed consent

Exclusion Criteria:

* Acute coronary syndrome
* Acute myocardial infarction \<6 months
* Planned cardiac surgery or cardiovascular intervention within 6 months following inclusion
* Valvular heart disease \>2°
* Severe comorbidities with limited life expectancy \<12 months
* Precapillary pulmonary hypertension
* Participation in another trial

Primary outcomes:
measure: Hemodynamic parameter 1: Changes in contractility assessed by the end-systolic pressure-volume relationship
timeFrame: Day 1
Secondary outcomes:
measure: Hemodynamic parameter 2: Changes in contractility assessed by the peak power index
timeFrame: Day 1
measure: Hemodynamic parameter 3: Changes in relaxation assessed by the relaxation constant "tau"
timeFrame: Day 1
measure: Functional parameter: Changes in ejection fraction
timeFrame: Day 1
Other outcomes:
Locations:
city: Lübeck
country: Germany
facility: Universitätsklinikum Schleswig-Holstein
state: Schleswig-Holstein
Study officials:
References: